Inactive Instrument

Neuralstem, Inc. Stock NYSE

US64127R3021

End-of-day quote NYSE Other stock markets
- ^USD	-

06-11	Palisade Bio, Inc. Announces Board Appointments	CI
05-12	Palisade Bio Inc - may offer and sell up to $300 million of securities - SEC filing	RE

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Latest news : Neuralstem, Inc.

06-11	Palisade Bio, Inc. Announces Board Appointments	CI
05-12	Palisade Bio Inc - may offer and sell up to $300 million of securities - SEC filing	RE
05-12	Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Palisade Bio Inc Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure And Sustained IC90 Coverage Supporting Once-Daily Dosing In Ulcerative Colitis	CI
03-31	Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease	MT
03-30	Palisade Bio Says Phase 1b Data Supports PALI-2108's Development as Potential Treatment for Fibrostenotic Crohn's Disease	MT
03-30	Palisade Bio, Inc. Reports Positive Topline Data From Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn?s Disease	CI
03-26	Palisade Bio, Inc. announced that it has received $3 million in funding from Iterative Scopes, Inc.	CI
03-26	HC Wainwright Initiates Coverage on Palisade Bio With Buy Rating, $7 Price Target	MT
03-20	Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-25	Stifel Initiates Palisade Bio at Buy With $5 Price Target	MT
02-23	Palisade Bio, Inc. Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 At ECCO 2026	CI
02-17	Palisade Bio, Inc. Appoints Bram Verstockt to Clinical Advisory Board	CI

More news

Analysts' recommendations: Neuralstem, Inc.

03-26	HC Wainwright Initiates Coverage on Palisade Bio With Buy Rating, $7 Price Target	MT
02-25	Stifel Initiates Palisade Bio at Buy With $5 Price Target	MT
01-09	B. Riley Initiates Palisade Bio at Buy With $7 Price Target	MT
23-11-17	Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	MT
23-05-16	Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating	MT

More recommendations

Press Releases: Neuralstem, Inc.

06-11	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors	AQ
06-10	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium	AQ
06-09	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium	AQ
05-27	Palisade Bio to Participate in the Jefferies Global Healthcare Conference	AQ
05-12	Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108	AQ

More press releases

News in other languages: Neuralstem, Inc.

24-01-29	MÄRKTE USA/Fester - Neue Rekordhochs dank sinkender Anleihezinsen
24-01-29	LATE BRIEFING - Unternehmen und Märkte
24-01-29	MÄRKTE USA/Kaum verändert - Vor Fed-Entscheid dominiert Zurückhaltung
24-01-29	MÄRKTE USA/Wall Street startet wenig verändert in Fed-Woche
24-01-29	MÄRKTE USA/Wall Street wenig verändert erwartet

More news

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Employees

Sector

More about the company

Market Cap	298M 257M 236M 222M 417M 28.18B 421M 2.79B 1.09B 13.8B 1.12B 1.09B 47.82B	P/E Ratio 2026 *	-8.48x	P/E Ratio 2027 *	-7.57x
Enterprise Value	204M 176M 162M 152M 285M 19.27B 288M 1.91B 745M 9.44B 765M 749M 32.7B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

	2026 *	2027 *
Net sales	-	-
Net income	-44.14M -38.04M -35.03M -32.89M -61.75M -4.17B -62.4M -414M -161M -2.04B -166M -162M -7.08B	-52.03M -44.84M -41.29M -38.77M -72.79M -4.92B -73.56M -488M -190M -2.41B -195M -191M -8.35B
Net Debt	-94.2M -81.18M -74.76M -70.19M -132M -8.91B -133M -883M -344M -4.36B -354M -346M -15.11B	-331M -285M -263M -247M -463M -31.31B -468M -3.11B -1.21B -15.33B -1.24B -1.22B -53.14B

Neuralstem, Inc. Stock NYSE

Stocks

US64127R3021

Valuation: Neuralstem, Inc.

Latest news : Neuralstem, Inc.

Analysts' recommendations: Neuralstem, Inc.

Press Releases: Neuralstem, Inc.

News in other languages: Neuralstem, Inc.

Financials

Company Profile